10 Biggest Price Target Changes For Tuesday
Benchmark cut the price target for JD.com, Inc. (NASDAQ: JD) from $112 to $102. JD.com rose 8.5% to $71.32 in pre-market trading.
The Daily Biotech Pulse: Cara’s Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 23)
Cowen & Co. Downgrades Theravance Biopharma to Market Perform, Lowers Price Target to $14
Cowen & Co. analyst Marc Frahm downgrades Theravance Biopharma (NASDAQ:TBPH) from Outperform to Market Perform and lowers the price target from $42 to $14.
SVB Leerink Maintains Outperform on Theravance Biopharma, Lowers Price Target to $29
SVB Leerink analyst Geoffrey Porges maintains Theravance Biopharma (NASDAQ:TBPH) with a Outperform and lowers the price target from $37 to $29.
Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study
Theravance Biopharma Inc’s (NASDAQ:TBPH) Izencitinib, a “gut-selective” JAK inhibitor developed for ulcerative colitis and Crohn’s disease, failed a key Phase…
Needham Maintains Buy on Theravance Biopharma, Lowers Price Target to $18
Needham analyst Joseph Stringer maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and lowers the price target from $32 to $18.
HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $21
HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and lowers the price target from $32 to $21.
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows.